Special Issue

The Exciting Opportunities That Radiopharmaceuticals Have to Offer: Nuclear Medicine Imaging, Therapy and Drug Delivery Systems

Message from the Guest Editors

Radiopharmaceuticals play a transformative role in nuclear medicine by enabling both precise imaging and targeted treatment at the molecular level. Recent innovations in radiochemistry, molecular probe design, and drug delivery platforms have significantly enhanced the specificity, bioavailability, and therapeutic index of these agents. Advances in targeted radionuclide therapy (TRT) have opened up new therapeutic pathways for combatting cancer and inflammatory diseases. At the same time, engineering drug delivery systems—such as nanocarriers and ligand-conjugated scaffolds—has improved the in vivo stability, biodistribution, and cell/tissue penetration of radiopharmaceuticals. This Special Issue aims to gather original research and reviews on cutting-edge developments in the design, synthesis, and application of radiopharmaceuticals for both diagnostic and therapeutic purposes. Topics of interest include novel imaging probes, PET/SPECT tracers, theranostic agents, and innovative drug delivery approaches for crossing biological barriers. Contributions highlighting the translational and clinical potential of radiopharmaceuticals are particularly welcome.

Guest Editors

Dr. Yanli Wang

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA

Dr. Ralph Santos-Oliveira

- 1. Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil
- 2. Laboratory of Nanoradiopharmacy, Rio de Janeiro State University, Rio de Janeiro 23070-200, Brazil

Deadline for manuscript submissions

30 November 2025



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/243902

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

